RUNX
All Product Categories
-
RUNX Related Products (12)
Related Products (12)
- 1
-
AI-10-49
0 ImagesAI-10-49 is an inhibitor of leukemic oncoprotein CBFβ-SMHHC. AI-10-49 inhibits the binding of CBFβ-SMMHCto the RUNX1 Runt domain with IC50 value of 0.26 μM. AI-10-49 can be used for the research of leukemia.
-
Withanolide B
0 ImagesWithanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects.
-
RUNX1/ETO tetramerization-IN-1
0 ImagesRUNX1/ETO tetramerization-IN-1 is a small-molecule inhibitor of RUNX1/ETO tetramerization, exhibits anti-leukemic effect. RUNX1/ETO tetramerization-IN-1 specifically targets to NHR2 of RUNX1/ETO (EC50=0.25 μM), restores gene expression down-regulated by RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 inhibits the proliferation of RUNX1/ETO-depending SKNO-1 cells, and reduces the RUNX1/ETO-related tumor growth in a mouse model.
-
AI-10-47
0 ImagesAI-10-47 is a small molecule inhibitor of CBFβ-RUNX binding, with an IC50 of 3.2 μM.
-
AI-4-57
0 ImagesCat. No.: HY-125966CAS No.: 63053-14-5AI-4-57 is an allosteric inhibitor for CBFβ SMMHC-RUNX1 (core binding factor β and the smooth-muscle myosin heavy chain) interaction with an IC50 of 22 μM.
-
RUNX1/ETO-IN-1
0 ImagesCat. No.: HY-174367CAS No.: 923865-06-9RUNX1/ETO-IN-1 is a RUNX1-ETO oncogenic fusion protein inhibitor that specifically targets the NHR2 oligomerization domain. RUNX1/ETO-IN-1 directly interacts with the NHR2 (KD,app = 39 μM). RUNX1/ETO-IN-1 exhibits anti-leukemic activity by inducing apoptosis and promoting differentiation in RUNX1/ETO-translocated AML cells. RUNX1/ETO-IN-1 remains essentially uncharged at physiological pH, demonstrating superior membrane permeability.
-
NSC 140873
0 ImagesCat. No.: HY-118365CAS No.: 106410-13-3NSC 140873 is an inhibitor of the RUNX1-CBFβ interaction. NSC 140873 can be used for research of viral infection and leukemia. NSC 140873 has an unstable structure and can be converted spontaneously in solution to a benzodiazepine (Ro5-3335).
-
Runx1-CBFβ interaction inhibitor 1
0 ImagesCat. No.: HY-124137CAS No.: 493028-20-9Runx1-CBFβ interaction inhibitor 1 is an allosteric inhibitior of Runt domain-CBFb interaction (IC50=3.2 μM).
-
Withanolide B (Standard)
0 ImagesCat. No.: HY-129566RCAS No.: 56973-41-2Withanolide B (Standard) is the analytical standard of Withanolide B. This product is intended for research and analytical applications. Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects.
-
Ro5-3335 (Standard)
0 ImagesCat. No.: HY-108470RCAS No.: 30195-30-3Ro5-3335 (Standard) is the analytical standard of Ro5-3335 (HY-108470). This product is intended for research and analytical applications. Ro5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation.
-
Anti-osteoporosis agent-6
0 ImagesCat. No.: HY-155985CAS No.: 445231-36-7Anti-osteoporosis agent-6 (compound 174) is an anti-osteoporosis agent. Anti-osteoporosis agent-6 has 14.11% inhibition rate against osteoclast formation at 10 μM.
- 1
